Argos Therapeutics (ARGS) Receiving Somewhat Favorable News Coverage, Report Shows
News coverage about Argos Therapeutics (NASDAQ:ARGS) has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Argos Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.371817618583 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Unusual Activity Spotted in Argos Therapeutics Inc (ARGS) – Sheridan Daily (sheridandaily.com)
- ETFs with exposure to Argos Therapeutics, Inc. : August 31, 2017 (finance.yahoo.com)
- Stock Trading Watch for Argos Therapeutics Inc (ARGS) – Danville Daily (danvilledaily.com)
- The Bottom Line on Argos Therapeutics, Inc. (ARGS), Tandem Diabetes Care, Inc. (TNDM) – AllStockNews (allstocknews.com)
- Dissecting the Investment Cases for Dr Pepper Snapple Group, Inc. (DPS) and Argos Therapeutics, Inc. (ARGS) – Economic News (economicsandmoney.com)
Argos Therapeutics (NASDAQ:ARGS) traded up 0.2007% on Friday, reaching $0.1997. The company’s stock had a trading volume of 1,232,125 shares. Argos Therapeutics has a 52 week low of $0.18 and a 52 week high of $5.68. The company has a 50 day moving average of $0.24 and a 200 day moving average of $0.64. The firm’s market capitalization is $10.98 million.
Argos Therapeutics (NASDAQ:ARGS) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. Argos Therapeutics had a negative return on equity of 1,532.49% and a negative net margin of 12,391.15%. The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.10 million. On average, analysts forecast that Argos Therapeutics will post ($1.14) earnings per share for the current year.
Separately, Zacks Investment Research downgraded Argos Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 14th. One analyst has rated the stock with a sell rating and three have given a hold rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $3.23.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Stock Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related stocks with our FREE daily email newsletter.